Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Azra Raza(University of Illinois Chicago), Mikkael A. Sekeres(University of Miami), John E. Godwin(Providence Portland Medical Center), Deborah Mulford(University of Rochester), Marsha Jones, Naomi Galili(Columbia University Irving Medical Center), Lisa Meng(Cytokinetics (United States)), Han Myint(Denver Health Medical Center), Daruka Mahadevan(The University of Texas MD Anderson Cancer Center), Scott E. Smith(Loyola University Medical Center), Gail L. Brown(Palo Alto Institute), O.O. Melnyk(Bay Area Cancer Connections), Mary Ann Allison(Cornell University), Mark U. Rarick(Kaiser Permanente), Ralph V. Boccia(Center for Cancer and Blood Disorders), Shelby Young(Palo Alto Institute)
Cited by 2
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Age and acute myeloid leukemia
|Blood|2006|1.4k